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• First cost-effectiveness analysis of a potential hexavalent GBS vaccine in a low-resource setting 22 
• A hexavalent GBS vaccine could avert 55% of Gambian cases and 768 disability adjusted life years 23 
per year  24 
 25 
• Maximum cost-effective price per dose would be 12 US$ (2016 US$) 25 
• GBS incidence was the most influential parameter on the cost effectiveness ratio.   26 
 25 
ABSTRACT 27 
Objective: To estimate neonatal health benefits and healthcare provider costs of a theoretical Group 28 
B streptococcal (GBS) hexavalent maternal vaccination programme in The Gambia, a low-income 29 
setting in West Africa. 30 
Methods:  A static decision analytic cost-effectiveness model was developed from the healthcare 31 
provider perspective. Demographic data and acute care costs were available from studies in the 32 
Gambia undertaken in 2012-2015. Further model parameters were taken from United Nations and 33 
World Health Organisation sources, supplemented by data from a global systematic review of GBS 34 
and literature searches. As vaccine efficacy is not known, we simulated vaccine efficacy estimates of 35 
50-90%.  Costs are reported un US dollars. Cost-effectiveness thresholds of one (US$473, very cost 36 
effective) and three (US$1420, cost effective) times Gambian GDP were used.  37 
Results: Vaccination with a hexavalent vaccine would avert 24 GBS disease cases (55%) and 768 38 
disability adjusted life years compared to current standard of care (no interventions to prevent GBS 39 
disease). At vaccine efficacy of 70%, the programme is cost-effective at a maximum vaccine price per 40 
dose of 12 US$ (2016 US$), and very cost-effective at a maximum of $3/dose. The total costs of 41 
vaccination at $12 is $1,056,962 for one annual cohort of Gambian pregnant women. One-way 42 
sensitivity analysis showed that GBS incidence was the most influential parameter on the cost 43 
effectiveness ratio.  44 
Conclusion: The introduction of a hexavalent vaccine would considerably reduce the current burden 45 
of GBS disease in The Gambia but to be cost-effective, the vaccine price per dose would need to be 46 
$12/dose or less. 47 
 48 
  49 
 25 
INTRODUCTION 50 
Group B streptococcus (GBS) is a leading cause of neonatal sepsis and meningitis worldwide and can 51 
lead to disabling long-term sequelae in up to 50% of meningitis survivors (1). A key focus for the 2030 52 
sustainable development goals (SDGs) is to reduce the neonatal mortality rate (NMR) to 12/1000 53 
livebirths in every country globally (2). The NMR in The Gambia, a low-income West-African country, 54 
has remained static over the past 10 years at 28/1000 livebirths. (3) Since 44% of under-five deaths 55 
occur during the neonatal period (first 28 days of life), and infection causes 51.8% of under-five 56 
mortality worldwide, tackling neonatal GBS infection could significantly reduce neonatal mortality 57 
(4,5).  58 
Maternal vaccination against GBS is a global priority identified by the World Health 59 
Organisation (WHO) (6). Several maternal multivalent GBS capsular polysaccharide (CPS) protein-60 
conjugate vaccines are currently undergoing Phase I/II randomised control trials (RCTs) in Europe, 61 
the USA and South Africa (7). A multivalent protein-based vaccine is also undergoing phase I/II trials 62 
in Europe. (8) Vaccines specifically for low- and middle-income countries (LMIC) are being developed 63 
using tetanus toxoid (TT) conjugates which could potentially replace one of the tetanus doses given 64 
in pregnancy in LMICs (7). Nevertheless, there is little information for healthcare providers about the 65 
vaccine’s potential cost-effectiveness in low-income countries. An important criteria for a licensed 66 
GBS vaccine’s adoption into Gavi, the Vaccine Alliance’s portfolio, would be to demonstrate cost-67 
effectiveness in low-income countries (9). 68 
Previous cost-effectiveness studies of GBS vaccines (10)  in low-income African countries such 69 
as Ghana exist but these models exclude countries such as the Gambia, which have far lower Gross 70 
Domestic Product (GDP), health spending and access to care than Ghana (which achieved middle 71 
income status in 2012) (11). The Gambia has relatively good health and cost information that allows 72 
the potential impact of a GBS vaccine to be evaluated (12,13). This study aims to more accurately 73 
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inform policymakers on the potential economic impacts and neonatal health benefits of a maternal 74 




Target population, subgroups, setting  79 
Demographic data from a previously conducted prospective study of 750 mother-infant pairs from 80 
two government health centres in urban Western Gambia in 2014 (12,500 livebirths annually) 81 
identified risk factors for GBS colonisation, transmission to neonates and GBS disease. New-borns 82 
were followed until 90-days of age for disease, mortality and disability outcomes. There was one case 83 
of culture-positive GBS disease, giving an incidence of 1.3/1000 livebirths (12). This data represents 84 
a sample of convenience and the government hospitals selected represent the standard of care 85 
available to Gambian women and is thus representative of neonatal care in the Gambia (13,14).  86 
 87 
Where GBS data from this cohort was unavailable, the following hierarchy of data were selected: 88 
local data from a neonatal infection study  (13) and a cost analysis of pneumococcal disease 89 
treatment (15), country-specific data from the Institute for Health Metrics Evaluation (IHME), UN 90 
International Children’s Emergency Fund (UNICEF) and WHO global health observatory (GHO) 91 
(3,5,14) (Table 1). For the remaining parameters, a literature review on PubMed was conducted (15–92 
19). [Appendix 1 and 2] 93 
 94 
Disability adjusted life year (DALY) measures  95 
DALYs associated with each disease sequalae were calculated using disability weights from The Global 96 
Burden of disease (GBD) study 2016 (20). GBS-specific weights are unavailable so non-specific proxies 97 
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were used for each disease presentation. (20,21) [Table 1]. Life expectancy for those with disability 98 
was assumed to be 30 years based on neighbouring Senegal (22). The rates of GBS sequelae including 99 
from meningitis were sourced from other studies as long-term sequelae were unavailable in the 100 
Gambia (17,19,23). 101 
 102 
Costs of disease treatment 103 
Costs of treating neonatal patients were taken from a cohort study of neonatal sepsis at the Edward 104 
Frances Small Teaching Hospital from 2014 (13). As no separate costs for the treatment of pneumonia 105 
or meningitis or costs of sequelae of meningitis were available from this study, costs were taken from 106 
cost-effectiveness analysis of treating young infant and paediatric patients aged 4-24 months with 107 
pneumococcal disease in the Gambia, as the costs of treating GBS disease in neonates and young 108 
infants was deemed to be similar, based on similar length of treatment and cost of sequelae other 109 
than death (15). Family out-of-pocket costs for the care of GBS survivors were also sourced from this 110 
study. All prices were inflated to 2016 US$ using standard annual inflation rates (24). The length of 111 
stay was adjusted for neonates using local data on neonatal stay for non-specific meningitis, 112 
pneumonia and sepsis (13). [Appendix 3] 113 
 114 
Intervention - Vaccine uptake was assumed to be 84.3%, the same as that for the tetanus toxoid (TT) 115 
vaccine in the Gambian study (12), assuming single dose late-third-trimester vaccination to replace 116 
one tetanus toxoid dose as per WHO recommendations (25). Vaccine wastage rate is assumed to be 117 
10% (26). The vaccine efficacy is currently unknown, so the model was run at efficacies of 50%, 70% 118 
and 90% (10). Multiplying the estimated 97% serotype coverage of a multivalent vaccine by these 119 
efficacy rates provided a range of vaccine coverage from 48.5% - 87.3% for term infants. Vaccine 120 
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efficacy for pre-terms was calculated to be 83.1% of the efficacy for term babies. [Appendix 4] The 121 
maximum cost-effective price per dose includes the cold storage for a new vaccine. 122 
 123 
Study perspective – The study is written from the perspective of the healthcare provider with 124 
additional out-of-pocket costs for families caring for affected neonates, explored in further analysis.  125 
 126 
The model 127 
A decision-analytic model was developed in R (fig. 1) from an existing UK model of GBS 128 
vaccination introduction (27). The model estimates a maximum vaccine price per dose threshold 129 
whereby a hexavalent CPS-TT third trimester GBS vaccination programme would be deemed cost-130 
effective in the Gambia using GDP per capita calculations. The programme is deemed cost-effective, 131 
at a cost/DALY averted of less than 1420 US$, three times the Gambian Gross Domestic Product per 132 
capita (GDPpc) and  very cost-effective if the cost/DALY averted is less than 473 US$, one times GDPpc 133 
(28,29). 134 
The model assesses infant health outcomes from birth to 90 days of age of no intervention 135 
compared to the proposed strategy of vaccination. Beyond one year after birth, an annual discount 136 
rate of 3% (26) was applied to infant life years lost and healthcare costs for GBS disease survivors 137 
(27). Key model inputs for the base-case population are in Table 1. 138 
 139 
A decision tree, created on LucidChart, illustrates the individual state-transition model with either 140 
strategy via embedded Markov nodes. The expectant mother can either be vaccinated or not. Each 141 
livebirth may be preterm or term infants who are GBS disease-free or GBS disease sufferers, defined 142 
as pneumonia, meningitis or sepsis (30). The infant is assumed to suffer from sepsis, meningitis or 143 
pneumonia independently and may recover without sequelae, disabling sequelae or death. Both 144 
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early (EOD) and late-onset disease (LOD) are generalised as GBS disease, as Gambian data was 145 
unavailable. We were unable to undertake situational analysis of stillbirths in the Gambia because 146 
this association was not investigated during any of the cohort studies. [Fig. 1.] The results are 147 
reported using the CHEERS checklist (31) 148 
 149 
Sensitivity analysis 150 
A one-way sensitivity analysis was carried out to show the uncertainty associated with each 151 
key parameter and its impact on the cost-effectiveness of the programme. One parameter at a time 152 
was varied to the maximum and minimum values of its range [table 1] whilst all other parameters 153 
were held to their base-case values. Probabilistic sensitivity analysis was used to determine the level 154 
of uncertainty associated with the calculated cost-effectiveness threshold by varying parameters 155 
simultaneously whilst keeping vaccine price per dose fixed. Cost-effectiveness acceptability curves 156 
were generated from 5000 simulated outcomes for prices $3 and $12. 157 
 158 
Ethics Approval 159 
This study was approved by the joint MRC Gambian Government research ethics committee, 160 
L2018.61, SCC 1350v4. 161 
  162 
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RESULTS  163 
No intervention 164 
With no intervention, at a GBS disease incidence in the Gambia of 1.3/1000 livebirths (12), an 165 
annual cohort of 89,000 livebirths (32) would face 116 cases: 25 babies would suffer from meningitis; 166 
50 babies from sepsis; and 41 from pneumonia. 14 babies would have sequelae (meningitis=5, 167 
sepsis=9). There would be 44 GBS deaths (meningitis=5, pneumonia=14, sepsis=25) and 1384 DALYs.  168 
The total costs of no intervention for the healthcare provider are $15,373, which comprises hospital 169 
admission, hospital length of stay of 6, 10 and 11 days for babies with sepsis, pneumonia and 170 
meningitis respectively and the costs of antibiotics and fluid support. [Appendix 4] Family out-of-171 
pocket costs would be $5,270; $376 per family caring for a child with GBS sequalae [Table 2]. 172 
 173 
Vaccination outcomes 174 
At a calculated base-case vaccine efficacy for term infants of 70% and when serotype coverage is 175 
97%, GBS vaccination could avert 55% of all outcomes, i.e. 768 DALYs, 64 GBS disease cases, seven 176 
GBS sequelae and 24 neonatal/young infant deaths. The provider treatment costs averted with 177 
vaccination are $6937, $9738 and $12,704 at vaccine efficacies 50%, 70% and 90% respectively. The 178 
family out-of-pocket cost savings range between $2084, $2926 and $3817 for vaccine efficacies 50%, 179 
70% and 90% respectively. This represents twice to four times the annual minimal wage in the 180 
Gambia of $1610 (33). The total programme costs for 89,000 pregnancies in one year would be 181 
$1,056,962 per year. There are very modest GBS disease treatment cost savings for the healthcare 182 
provider of $9738 per year. Total family out of pocket costs per year (outside of the cost-effectiveness 183 




Assuming 70% vaccine efficacy, the maximum cost-effective price per dose is $12 per dose. 187 
The cost/DALY averted would be $1355, below the benchmark of three times the Gambian GDP per 188 
capita ($1420). [Table 3] This maximum cost-effective price per dose would range from $8 to $16 at 189 
vaccine efficacies of 50% and 90% respectively.  190 
At $3/dose, the vaccination programme is very cost-effective at $365/DALY averted assuming 191 
70% vaccine efficacy which is below the benchmark cost of $474 (GDPpc in the Gambia). [Fig. 2] The 192 
incremental cost of the programme is $264,658. The treatment cost savings ($8534) are independent 193 
of vaccine price per dose. The total programme costs are $295,404.  194 
 195 
Sensitivity analysis 196 
The tornado diagram [Fig. 3.] shows that the most influential parameter is the vaccine price per dose. 197 
At $2 per dose, the cost effectiveness ratio (CER) is $253/DALY averted and at $20 per dose, the CER 198 
is $2233/DALY averted. GBS incidence is the second most influential parameter. At a low GBS 199 
incidence (0.73/1000 livebirths), the CER is more than double at $2419/DALY averted. The least 200 
influential parameters are GBS disease treatment costs. For example, treating pneumonia at $88.8-201 
$159 leads to a CER ranging from $1354-1352. 202 
For the base case scenario, probabilistic sensitivity analysis was carried out at vaccine prices of $3 203 
and $12 per dose. According to uncertainty guidelines, at least 90% of iterations need to be under 204 
the CER of $1419.6 (34). At $3/dose, 99.92% of iterations are below this threshold, while at a vaccine 205 
price per dose of $12, 18.12% of iterations fall under the CER. These outcomes demonstrate the 206 
influence of vaccine price on the GBS vaccine cost-effectiveness. [Fig. 4.] 207 
Comparing the impact of disease incidence and vaccine efficacy on the results of the 208 
probabilistic sensitivity analysis, Fig. 5. shows that vaccine efficacy is the most influential of the two. 209 
Table 1 displays parameter values tested. 210 
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The cost-effectiveness acceptability curve in Fig. 6. shows how likely vaccination is to be cost-211 
effective over doing nothing as willingness and ability to pay increases from 0 to $6000/DALY.  While 212 
over 80% of iterations are cost-effective for willingness to pay of at least $1000/DALY when vaccine 213 
price is at $3/dose, a vaccine price of $12/dose means that similar cost-effectiveness levels are 214 
achieved at a willingness to pay of at least $3000/DALY.  215 
 216 
DISCUSSION 217 
Over a one-year period, an affordable, effective maternal GBS vaccine could prevent 768 218 
DALYs, 64 cases, 24 neonatal and infant deaths and seven severely disabled survivors (55% of disease-219 
burden) at a base-case vaccine efficacy of 70% in the Gambia.  For higher vaccine efficacy of 90%, up 220 
to 72% of the disease burden could be prevented. However, we found that the costs of the standard 221 
of care for GBS were very modest, which reflects the limited facility to treat affected babies beyond 222 
antibiotic administration.  223 
 In order to be cost-effective, our model suggests that such a vaccine would have to be 224 
provided at a low cost of approximately $12 per dose at 70% efficacy ($8 and $16 for 50% and 90% 225 
efficacy respectively) and $3 assuming a threshold of the Gambian GDP per capita. The net annual 226 
cost of a GBS vaccination programme at $12 per dose would be $1,056,962. A three times GDP per 227 
capita threshold allows comparison of our study with others but this threshold may be an 228 
unrealistic option for The Gambia where budgets are especially constrained and resources may be 229 
allocated to other sectors (17,35). It is clear from this and other GBS cost-effectiveness studies in 230 
LMICs, that only modest vaccine prices could be supported, and affordability should be an 231 
important criterium for vaccine development. Our cost-effective price of $12 per dose and highly 232 
cost-effective price of $3 per dose is in line with other vaccinations provided to GAVI-eligible 233 
countries. For example, the pneumococcal conjugate vaccine (PCV 13) provided by Pfizer, also 234 
 25 
recommended by the WHO for pregnant women is priced at $2.90 per dose to the 73 GAVI eligible 235 
countries (36) and the pentavalent vaccine (tetanus, haemophilus influenzae type B, diptheria, 236 
pertussis and hepatitis B is available to GAVI-eligible countries at $3/dose (37)  237 
 238 
Published studies have estimated a higher threshold price for a GBS vaccine. In South Africa 239 
at a vaccine price per dose of $20, the cost-effectiveness ratio at 70% vaccine efficacy is $1533 per 240 
DALY averted (10). In the Gambia, if the same vaccine price was used the CER would be $2231 per 241 
DALY averted. As there is a higher base-case-value of neonatal GBS disease incidence in South Africa 242 
(a middle-income country), the ability of the vaccine to prevent disease appears greater. This, 243 
combined with their higher treatment costs, leads to greater cost savings after introducing the 244 
vaccine in South Africa than in the Gambia (10).  245 
There are several differences between our CEA and other models.  Firstly, our study used the 246 
data from a neonatal and infant cohort to provide information on GBS disease. We included an 247 
estimate of GBS attributable pneumonia (10,17,38), which was not included in other cost-248 
effectiveness analyses of GBS vaccines. As most infants with pneumonia will die without prompt 249 
recognition and treatment, the addition of pneumonia is important in reducing the burden of death 250 
in the neonatal and early infant period (39). The most influential factor in our sensitivity analysis was 251 
disease incidence, indicating that investments in surveillance are most likely to reduce uncertainty 252 
on cost-effectiveness. 253 
 The sub-Saharan Africa (SSA) study clustered countries with similar socio-economic 254 
backgrounds together making generalised assumptions about healthcare settings. (17) Using Ghana 255 
as an example of a low income country,  the maximum cost-effective vaccine price per dose is $7 at 256 
$350/DALY averted at a vaccine efficacy of 70%. (17) When our study is adjusted to these 257 
assumptions, however, the CER is $544/DALY which is higher than this estimate likely due to our 258 
 25 
lower disease incidence. Both previous studies assumed effectiveness from a trivalent vaccine, yet 259 
without serotype V, which is included in our study, such a vaccine would be less cost-effective in the 260 
Gambia. Differences in income and treatment costs in both the South Africa and the SSA study make 261 
comparisons between these studies and ours difficult. For example, in South Africa, the average 262 
length of hospital stay for neonatal meningitis was 17 days whilst in both the SSA and our study the 263 
median length of stay was 11 days. (15,40).  264 
In comparison to other vaccines in the infant extended programme on immunisation in the 265 
Gambia, a GBS vaccine could be more cost-effective than the 13-valent pneumococcal conjugate 266 
vaccine (PCV). The PCV cost-effectiveness study  measured the same disease presentations as our 267 
study, but only 65% of DALYs were averted compared to 72% for the GBS vaccine at 90% vaccine 268 
efficacy using similarly conservative estimates, making an effective case for the introduction of this 269 
hexavalent vaccine to prevent all forms of GBS disease in the Gambia. (26)  270 
There are limitations to this study. This analysis is based on a single study of 750 women 271 
delivering in costal Gambia and, although this is the largest study of GBS disease in a low income 272 
setting, may not be representative of GBS incidence in the whole of the Gambia or other low 273 
income countries. Nonetheless the incidence used in our model is consistent with estimates of 274 
disease burden for Western Africa (41) We included only adult pregnant women and as 8.8% of 275 
pregnancies in the Gambia occur in women aged between 15-19 years our study may have 276 
underestimated vaccine impact in this vulnerable group as low maternal age is a risk factor for 277 
neonatal GBS disease (42,43). The static model used, which has been used for other cost 278 
effectiveness studies of GBS vaccine, does not enable us to assess potential changes in the 279 
incidence of GBS over time, or any indirect vaccine effects. Several other factors will affect the 280 
model and our results may therefore underestimate the cost-saving of a GBS vaccine. Firstly, the 281 
surveillance occurred over one year, and subsequent years may have revealed an increased disease 282 
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incidence which would increase the cost-effectiveness of our model. We were unable to include 283 
indirect costs as these are not currently defined for maternal vaccination. Finally, although we 284 
added family out of pocket costs to our model, we were unable to include all societal costs. For 285 
parameters such as neurodevelopmental impairment, country-specific data was not available, thus 286 
our estimates are derived from global estimates that may not represent The Gambia (19). However, 287 
the degree of disability due to GBS meningitis is similar to that of other bacterial meningitis in 288 
similar settings and this data was available from the Gambia.(15,23) Additionally, only GBS 289 
moderate-severe sequelae were included because data on mild sequelae rates are less reliable, 290 
especially in the Gambia. (19). Consequently, the model may underestimate some cases with 291 
sequelae and their associated DALYs. While treatment costs in our model were modest, we 292 
acknowledge that the length of hospital stay may vary for different causative pathogens. Only non-293 
pathogen specific costs were available since in most cases, blood cultures would not be taken 294 
because of constrained resources and the reliance on families to pay for these tests. We did not 295 
evaluate other options for GBS prevention and control as these were not available during the 296 
cohort study. There is limited data on the implementation of IAP in labour in the Gambia. The 297 
PregnAnZI trial (44) randomised 830 pregnant women in labour to have either a placebo or single-298 
dose oral azithromycin in Western Gambia and found that GBS colonisation was almost eliminated 299 
in mothers after azithromycin treatment. Azithromycin is more feasible than intravenous RFB-IA 300 
intravenous as it can be effective as late as two hours before delivery. Although this strategy has 301 
the potential to address EOD, more information is needed regarding its impact on antimicrobial 302 
resistance, the infant microbiome and other health outcomes before such a strategy can be widely 303 
recommended (44). The strategy would not reduce the burden of late onset disease, which most 304 
commonly presents as meningitis, so this burden would remain. Should this IAP strategy come into 305 




A vaccine that is modestly priced is likely to be a cost-effective intervention in reducing GBS disease 309 
in the Gambia. Uncertainty regarding cost-effectiveness can be reduced by improving estimates on 310 
the burden of GBS disease, particularly disease incidence.  311 
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Figure 1: Decision tree for cost effectiveness analysis.  511 
This diagram illustrates the two strategies in our model: the proposed Group B streptococcus (GBS) 512 
vaccination programme versus the current strategy of no intervention (no vaccination). Markov nodes 513 
denoted as M represent a continuation of the tree parallel to that of the other branch. For example, 514 
for both vaccination and no intervention, each livebirth can lead to GBS disease or no disease. GBS 515 
disease can present as sepsis, pneumonia or meningitis which can subsequently lead to death, 516 





2: Incremental cost-effectiveness ratio of running models at vaccine efficacies 50%, 70% and 90%.  521 
The maximum price per dose where the programme can be deemed cost effective (below the black 522 
hashed line) is $8, $12 and $16 at vaccine efficacies 50%, 70% and 90% respectively. The programme 523 
is deemed very cost-effective (below the red hashed line) at a maximum vaccine price per dose of $2, 524 
$4 and $5 at vaccine efficacies of 50, 70 and 90% respectively. DALY – disability adjusted life year; 525 
US$ - American dollars. 526 
 527 
 528 
Figure 3: A tornado diagram illustrating the uncertainty associated with key parameters in the 529 
model.  530 
Vaccine price per dose has the largest effect on the cost-effectiveness of the vaccination programme 531 
























Vaccine price per dose (US$)
Cost per DALY averted at 50% efficacy Cost per DALY averted at 70% efficacy
Cost per DALY averted at 90% efficacy Cost effective maximum threshold (1420 US$)
Very cost effective maximum threshold (473$)
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Figure 4a       Figure 4b 536 
Figure 4: Monte Carlo probabilistic sensitivity analysis 537 
Monte Carlo probabilistic sensitivity analysis of 23 parameters, 5000 iterations for base case scenario, 538 
for vaccine prices at $3/dose (figure 5a) and $12/dose (figure 5b).The incremental cost of the 539 
proposed immunisation strategy is plotted against the y axis with  the x axis displaying the 540 
incremental DALYs averted. Of the 5000 iterations, 99.92% fall below the cost effectiveness threshold 541 
of $1419.6 (red line) for the $3/dose case, while 18.12% fall below this threshold when the price is 542 




Figure 5a      Figure 5b 546 
Figure 5: Comparison of disease incidence and vaccine efficacy as drivers of vaccine cost-547 
effectiveness in terms of Cost per DALY averted.  548 
The chart represents Monte Carlo probabilistic sensitivity analysis of 5000 iterations, where other 549 
parameter values remain as in base case scenario. Vaccine price per dose for the base case scenario 550 
is $3 and $12 respectively (top to bottom). The incremental cost (£) per DALY averted of the maternal 551 
immunisation strategy compared to no preventative strategy is represented by nodes of varying 552 
colour depending on value (colour guides on figure’s right side). DALY: Disability-adjusted life year. 553 
DALY – disability adjusted life years. 554 
 555 
 556 
Figure 6a        Figure 6b 557 
 Cost-effectiveness acceptability curve of the base case scenario (future costs and discount 558 
rate = 3%).  559 
The graph displays the percentage of Monte Carlo iterations (total of 5000) for which the 560 
immunisation strategy is cost-effective, depending on the willingness of the healthcare system to pay 561 
 25 
(in $) for each DALY averted. Vaccine price per dose in the base case scenario is $3/dose (figure 6a)  562 
and $12/dose (figure 6b). 563 
  564 
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Table 1:  demographic data, rates of each disease outcome and their associated disability weights, 565 
vaccine parameters and costs associated with treatment and vaccination.  566 
Their ranges are included as a reference for the sensitivity analysis. Each source is included with 567 
relevant appendices, which include calculations of some parameters. ‘Local data’ refers to data from 568 
the Gambian cohort of mother-infant pairs studied. GBS – Group B Streptococcus 569 




Range Distribution Source 
Birth in the Gambia (annual)  
Number of pregnancies  94,482 -- -- (12,32)  
Number of livebirths  89,363 -- -- (32) 
Number of stillbirths  4866 -- -- (12,45)  
Number of preterm live 
births 
9./ 804 -- -- (12,45)  
Number of term 
livebirths  
69196 -- -- (12,45)  









Neonatal GBS disease 
incidence per 1000 
livebirths 
1.3 0.73-1.472 Uniform (12,17)  
Rate of meningitis due 
to GBS 
0.216 0.092-0.673 Uniform (12,17)  
Rate of sepsis due to 
GBS 
0.431 0.216-0.647 Uniform (12)  
Rate of pneumonia due 
to GBS 
0.353 0.177- 0.530 Uniform (12)  
Rate of sequelae from 
meningitis 
0.18 0.13-0.22 Uniform (19) 
Rate of sequelae from 
sepsis survivors 
0.369 0.127-0.381 Uniform (17) 
Death rate due to 
meningitis 
0.213 0.046-0.390 Uniform (18) 
Death rate due to 
sepsis  
0.500 0.250-0.750 Uniform (16)  
Death rate due to 
pneumonia 
0.333 0.167-0.500 Uniform (12)  
Serotype coverage (%) 97 0.873, 0.97, 1 Triangular( (12,30)  
Vaccine 
Vaccine efficacy in term 
babies (%) 
70 50-90 Uniform (10,17) 
Vaccine efficacy, 
preterm babies 
83.1% of term 
(0.582) 
0.416-0.748 -- (10,17) Appendix 3 
Vaccine uptake rate 84.3% 0.5-0.9 Uniform (12) Local data 
In patient, provider treatment costs per case 
Meningitis 309 253-478 Gamma (15) and (appendix) 
Sepsis 106 53.1-159 Gamma (15) and appendix 
Pneumonia 111 88.8-155 Gamma (15) and appendix 
Family out of pocket costs 
 25 
Meningitis 56.2   - (15) Appendix 4 
 
Sepsis 45.3   - (15) Appendix 4 
 
Pneumonia 38.5   - (15) Appendix 4 
Meningitis sequelae 9.66 0-41.8 Uniform (15) Appendix 4 
Disability weights 
Meningitis sequelae c 0.260 0.153 - 0.364 Uniform (21) 





per vaccinated woman 
($) 
0.456 0- 0.912 Gamma (48) 
Vaccine wastage rate 
(%) 
10 5-20 Uniform (48) 
 571 
  572 
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Table 2: Health outcomes and costs before vaccine introduction and after introduction of a 573 
vaccination programme at vaccine efficacies 50%, 70 and 90%.  574 
The numbers of cases are categorised into those attributable to sepsis meningitis and pneumonia. 575 
DALYs – Disability Adjusted Life Year; GBS – Group B Streptococcus; US$ - American dollars. 576 
 No vaccine Vaccine efficacy (%) 
50 70 90 
DALYs 
 
1384 837 616 395 
Number of disease cases  
 
116 70 52 33 
Cases averted, (% 
averted) 
 
 45.8 64.2 (55.5%) 82.7 (71.5%) 
Meningitis cases 
 
25 15 11 7 




41 25 18 12 
Number of GBS deaths  
 
44 27 20 13 
Number of deaths 
averted, 
 (% averted) 
 
 14 (32%) 24 (54.5%) 31 (70.5%) 
Meningitis deaths 
 
5 3 2 2 
Sepsis deaths  25 15 11 7 
     
Pneumonia deaths  
 
14 8 6 4 
Number of babies with 
sequelae  
 
13 8 6 4 
Number of sequelae 
averted, % 
 
 5 (40%) 7 (50%) 9 (71.5%) 
Meningitis sequelae cases  
 
4 2 2 1 
Sepsis sequelae cases  
 
9 6 4 3 
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 577 
Provider treatment costs 
(US$) 
17,542 10,604 7804 4837 
Out-of-pocket costs for 
treatment (US$) 
5270 3186 2345 1453 
Total treatment costs 
(US$) 
22,812 13,790 10,149 6290 
